Screener
Charles River Laboratories CRL Impact of acquisition and restructuring
Impact of acquisition and restructuring at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept crl:EffectiveIncomeTaxRateReconciliationImpactOfAcquisitionsAndRestructuringPercent.
The source filing: Charles River Laboratories’s 10-K, filed February 18, 2026.
- Filed
- Feb 18, 2026, 9:21 AM EST
- Fiscal year
- FY2025
- Accession
- 0001100682-26-000022
| Line item | Fiscal Year / 2024 | Fiscal Year / 2023 |
|---|---|---|
| Enacted tax rate changes | 3.0 | (0.1) |
| Tax on unremitted earnings | 10.7 | 1.7 |
| Impact of tax uncertainties | 0.6 | (0.3) |
| Impact of acquisitions and restructuring | 1.3 | (4.2) |
| Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA) | (0.9) | 0.2 |
| Global intangible low-taxed income | 6.3 | 1.5 |
| Foreign-derived intangible income | (7.6) | (1.4) |
| Goodwill impairment | 48.5 | — |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Charles River Laboratories's impact of acquisition and restructuring?
- Charles River Laboratories (CRL) reported impact of acquisition and restructuring of $0 in Q4 2024.
- How has Charles River Laboratories's impact of acquisition and restructuring changed year-over-year?
- Charles River Laboratories's impact of acquisition and restructuring increased by 131.0% year-over-year, from -$0.01 to $0.
- What does impact of acquisition and restructuring mean?
- Impact of acquisition and restructuring as reported by Charles River Laboratories International, Inc..
Ask your AI about Charles River Laboratories's impact of acquisition and restructuring.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude